Abstract
Metabolomics allows the simultaneous and relative quantification of thousands of different metabolites within a given sample using sensitive and specific methodologies such as gas or liquid chromatography coupled to mass spectrometry, typically in discovery phases of studies. Biomarkers are biological characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathological processes or pharmacologic responses to a therapeutic intervention. Biomarkers are widely used in clinical practice for the diagnosis, assessment of severity and response to therapy in a number of clinical disease states. In human studies, metabolomics has been applied to define biomarkers related to prognosis or diagnosis of a disease or drug toxicity/efficacy and in doing so hopes to provide greater pathophysiological understanding of disease or therapeutic toxicity/efficacy. This review discusses the application of metabolomics in the discovery and subsequent application of biomarkers in the diagnosis and management of inborn errors of metabolism, cardiovascular disease and cancer. We critically appraise how novel biomarkers discovered through metabolomic analysis may be utilized in future clinical practice by addressing the following three fundamental questions: (1) Can the clinician measure them? (2) Do they add new information? (3) Do they help the clinician to manage patients? Although a number of novel biomarkers have been discovered through metabolomic studies of human diseases in the last decade, none have currently made the transition to routine use in clinical practice. Metabolites identified from these early studies will need to form the basis of larger, prospective, externally validated studies in clinical cohorts for their future use as biomarkers. At this stage, the absolute quantification of these biomarkers will need to be assessed epidemiologically, as will the ultimate deployment in the clinic via routine biochemistry, dip stick or similar rapid at- or near-patient care technologies.
Similar content being viewed by others
References
Alfieri AB, Briceno L, Fragasso G, Spoladore R, Palloshi A, Bassanelli G, Montano C, Arioli F, Cuko A, Ruotolo G, Margonato A (2008) Differential long-term effects of carvedilol on proinflammatory and antiinflammatory cytokines, asymmetric dimethylarginine, and left ventricular function in patients with heart failure. J Cardiovasc Pharmacol 52(1):49–54
American Diabetes Association (2008) Diagnosis and classification of diabetes. Diabetes Care 31(Suppl 1):S55–S60
Anderson JL, Adams CD, Antman EM et al (2007) ACC/AHA 2007 guidelines for the management of patients with unstable Angina/Non ST-elevation myocardial infarction: a report of the American College of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 50(7):e1–e157
Arn PH (2007) Newborn screening: current status. Health Aff (Millwood) 26(2):559–566
Bassand JP, Hamm CW, Ardissino D et al (2007) Task force for diagnosis and treatment of non-ST-segment elevation acute coronary syndromes of European society of cardiology. Guidelines for the diagnosis and treatment of non-ST-elevation acute coronary syndromes. Eur Heart J 28:1598–1660
Begley P, Francis-McIntyre S, Dunn WB, Broadhurst DI, Halsall A, Tseng A, Knowles J, Goodacre R, Kell DB, Consortium H (2009) Development and performance of a gas chromatography-time-of-flight mass spectrometry analysis for large-scale nontargeted metabolomic studies of human serum. Anal Chem 81(16):7038–7046
Behar KL, Denhollander JA, Stromski ME, Ogino T, Shulman RG, Petroff OAC, Prichard JW (1983) High-resolution H-1 nuclear magnetic-resonance study of cerebral hypoxia in vivo. Proc Natl Acad Sci USA Biol Sci 80(16):4945–4948
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69(3):89–95
Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP (1998) Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842–1847
Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87:99–105
Brawer MK, Lange PH (1989) Prostate-specific antigen in management of prostatic carcinoma. Urology 33(5 Suppl):11–16
Brindle JT et al (2002) Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 8:1439–1444
Broadhurst DI, Kell DB (2006) Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics 2(4):171–196
Brown M, Dunn WB, Ellis DI, Goodacre R, Handl J, Knowles JD, O’Hagan S, Spasic I, Kell DB (2005) A metabolome pipeline: From concept to data to knowledge. Metabolomics 1(1):39–51
Bruggeman FJ, Westerhoff HV (2007) The nature of systems biology. Trends Microbiol 15(1):45–50
Bundy JG, Davey MP, Viant MR (2009) Environmental metabolomics: a critical review and future perspectives. Metabolomics 5(1):3–21
Cantor GH (2011) Metabolomics and mechanisms: sometimes the fisher catches a big fish. Toxicol Sci. doi:10.1093/toxsci/kfq297
Centerwall WR, Centerwall SA (1961) Phenylketonuria (FOLLING’s disease). The story of its discovery. J Hist Med Allied Sci 16:292–296
Chace DH, Kalas TA (2005) A biochemical perspective on the use of tandem mass spectrometry for newborn screening and clinical testing. Clin Biochem 38(4):296–309
Chen Y, Zhang R, Song Y, He J, Sun J, Bai J, An Z, Dong L, Zhan Q, Abliz Z (2009) RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst 134(10):2003–2011
Classen S, Staratschek-Jox A, Schultze JL (2008) Use of genome-wide high-throughput technologies in biomarker development. Biomarker Med 2(5):509–523
de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362:316–322
Dickstein K, Cohen-Solal A, Filippatos G et al (2008) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Eur Heart J 29(19):2388–2442
Dückelmann C, Mittermayer F, Haider DG, Altenberger J, Eichinger J, Wolzt M (2007) Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol 27(9):2037–2042
Dückelmann C, Mittermayer F, Haider DG, Altenberger J, Wolzt M (2008) Plasma asymmetric dimethylarginine and cardiovascular events in patients with acute decompensated heart failure. Transl Res 152(1):24–30
Dunckley T, Coon KD, Stephan DA (2005) Discovery and development of biomarkers of neurological disease. Drug Discovery Today 10(5):326–334
Dunn WB, Bailey NJC, Johnson HE (2005) Measuring the metabolome: current analytical technologies. Analyst 130(5):606–625
Dunn WB, Broadhurst DI, Deepak SM, Buch MH, McDowell G, Spasic G, Ellis DI, Brooks N, Neyses L, Kell DB (2007) Serum metabolomics reveals many novel metabolic markers of heart failure, including pseudouridine and 2-oxoglutarate. Metabolomics 3(4):413–426
Dunn WB, Broadhurst D, Atherton HJ, Goodacre R, Griffin JL (2011) Systems level studies of Mammalian metabolomes: the roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chem Soc Rev. doi:10.1039/B906712B
Ellis DI, Goodacre R (2006) Metabolic fingerprinting in disease diagnosis: biomedical applications of infrared and Raman spectroscopy. Analyst 131:875–885
Ellis DI, Dunn WB, Griffin JL, Allwood JW, Goodacre R (2007) Metabolic fingerprinting as a diagnostic tool. Pharmacogenomics 8:1243–1266
Fernandes J, Saudubray JM, Berghe G van d Walter JH (2006) Inborn metabolic diseases diagnosis and treatment 4th, rev. ed., XXII, 561, p 65 illus., Hardcover ISBN: 978-3-540-28783-4
Fiehn O (2002) Metabolomics—the link between genotypes and phenotypes. Plant Mol Biol 48(1–2):155–171
Folling A (1934) Ueber Ausscheidung von Phenylbrenztraubensaeure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillitaet. Ztschr Physiol Chem 227:169–176
Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24(19):1735–1743
Go EP (2010) Database resources in metabolomics: an overview. J Neuroimmune Pharmacol 5(1):18–30
Goodacre R (2007) Metabolomics of a superorganism. J Nutr 137:259S–266S
Goodacre R (2010) An overflow of… what else but metabolism! Metabolomics 6:1–2
Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB (2004) Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol 22(5):245–252
Goto T, Takase H, Toriyama T, Sugiura T, Sato K, Ueda R, Dohi Y (2003) Circulating concentrations of cardiac proteins indicate the severity of congestive heart failure. Heart 89(11):1303–1307
Griffin JL (2006) The Cinderella story of metabolic profiling: does metabolomics get to go to the functional genomics ball? Philos Trans R Soc B Biol Sci 361(1465):147–161
Guan W, Zhou M, Hampton CY, Benigno BB, Walker LD, Gray A, McDonald JF, Fernández FM (2009) Ovarian cancer detection from metabolomic liquid chromatography/mass spectrometry data by support vector machines. BMC Bioinform 10:259
Hall RD (2006) Plant metabolomics: from holistic hope, to hype, to hot topic. New Phytol 169(3):453–468
Hamada Y, Yamamura M, Hioki K, Yamamoto M, Nagura H, Watanabe K (1985) Immunohistochemical study of carcinoembryonic antigen in patients with colorectal cancer. Correlation with plasma carcinoembryonic antigen levels. Cancer 55(1):136–141
He W, Miao FJ, Lin DC, Schwandner RT, Wang Z, Gao J, Chen JL, Tian H, Ling L (2004) Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature 429(6988):188–193
Henkin TM (2008) Riboswitch RNAs: using RNA to sense cellular metabolism. Genes Dev 22(24):3383–3390
Hollywood K, Brison DR, Goodacre R (2006) Metabolomics: current technologies and future trends. Proteomics 6(17):4716–4723
Horning EC (1968) Use of combined gas-liquid chromatography and mass spectrometry for clinical problems. Clin Chem 14(8):777
Howells SL, Maxwell RJ, Peet AC, Griffiths JR (1992) An investigation of tumor H-1 nuclear-magnetic-resonance spectra by the application of chemometric techniques. Magn Reson Med 28(2):214–236
Hunt SA, Abraham WT, Chin MH et al (2005) ACC/AHA 2005 Guideline update for the diagnosis and management of chronic heart failure in the adult. American College of Cardiology. Circulation 112(12):e154–e235
Issaq HJ, Nativ O, Waybright T, Luke B, Veenstra TD, Issaq EJ, Kravstov A, Mullerad M (2008) Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry. J Urol 179(6):2422–2426
Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, Kristiansen G, Lein M, Jung K (2010) Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 58:12–18
Kell DB (2006) Metabolomics, modelling, machine learning in systems biology: towards an understanding of the languages of cells. The 2005 Theodor Bücher lecture. FEBS J 273:873–894
Kell DB (2007) Metabolomic biomarkers: search, discovery and validation. Exp Rev Mol Diagnost 7(4):329–333
Kell DB, Oliver SG (2004) Here is the evidence, now what is the hypothesis? The complementary roles of inductive and hypothesis-driven science in the post-genomic era. Bioessays 26:99–105
Kenny LC, Broadhurst D, Brown M, Dunn WB, Redman CWG, Kell DB, Baker PN (2008) Detection and identification of novel metabolomic biomarkers in preeclampsia. Reproduct Sci 15:591–597
Kenny LC, Broadhurst DI, Dunn WB, Brown W, North RA, McCowan L, Roberts C, Cooper GJS, Kell DB, Baker PN (2010) Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers. Hypertension 56:741–749
Kim K, Aronov P, Zakharkin SO, Anderson D, Perroud B, Thompson IM, Weiss RH (2009) Urine metabolomics analysis for kidney cancer detection and biomarker discovery. Mol Cellular Proteom 8(3):558–570
Kind T, Tolstikov V, Fiehn O, Weiss RH (2007) A comprehensive urinary metabolomic approach for identifying kidney cancer. Anal Biochem 363(2):185–195
Kirschenlohr HL, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, Clarke S, Schofield PM, McKilligin E, Mosedale DE, Grainger DJ (2006) Proton NMR analysis of plasma is a weak predictor of coronary artery disease. Nat Med 12:705–710
Kohler JP, Simonowitz D, Paloyan D (1980) Preoperative CEA level: a prognostic test in patients with colorectal carcinoma. Am Surg 46(8):449–452
Kuhara T (2007) Noninvasive human metabolome analysis for differential diagnosis of inborn errors of metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 855(1):42–50
Lewis GD, Wei R, Liu E, Yang E, Shi X, Martinovic M, Farrell L, Asnani A, Cyrille M, Ramanathan A, Shaham O, Berriz G, Lowry PA, Palacios IF, Taşan M, Roth FP, Min J, Baumgartner C, Keshishian H, Addona T, Mootha VK, Rosenzweig A, Carr SA, Fifer MA, Sabatine MS, Gerszten RE (2008) Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 118(10):3503–3512
Lindon JC, Nicholson JK (2008) Analytical technologies for metabonomics and metabolomics, and multi-omic information recovery. Trac-Trends Anal Chem 27(3):194–204
MacIntyre DA, Jiménez B, Lewintre EJ, Martín CR, Schäfer H, Ballesteros CG, Mayans JR, Spraul M, García-Conde J, Pineda-Lucena A (2010) Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. Leukemia 24(4):788–797
Madsen R, Lundstedt T, Trygg J (2010) Chemometrics in metabolomics—a review in human disease diagnosis. Anal Chim Acta 659(1–2):23–33
Mamas M, Dunn W, Broadhurst D, Chacko S, Brown M, El-Omar M, Fath-Ordoubadi F, Clarke B, Goodacre R, Kell D, Neyses L (2009) Serum metabolomics identifies novel signature metabolites in very early cardiac ischaemia: first in human study. Circulation 120:S892
Mashego MR, Rumbold K, De Mey M, Vandamme E, Soetaert W, Heijnen JJ (2007) Microbial metabolomics: past, present and future methodologies. Biotechnol Lett 29(1):1–16
Monod J, Wyman J, Changeux JP (1965) On the nature of allosteric transitions: a plausible model. J Mol Biol 12:88–118
Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949–952
Nam H, Chung BC, Kim Y, Lee K, Lee D (2009) Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 25(23):3151–3157
Nicholson JK (2006) Global systems biology, personalized medicine and molecular epidemiology. Mol Syst Biol 2:52
Nicholson JK, Lindon JC (2008) Systems biology—metabonomics. Nature 455(7216):1054–1056
Nicholson JK, Lindon JC, Holmes E (1999) ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29(11):1181–1189
Nicholson JK, Lindon JC, Holmes E, Wilson ID (2004) The challenges of modeling mammalian biocomplexity. Nat Biotechnol 22:1268–1274
Nikolaidou T, Mamas M, Oceandy D, Neyses L (2010) Biological action of alpha-ketoglutarate in the heart and kidney—a metabolite identified through a metabolomic search in patients with heart failure. Eur J Heart Failure Suppl 9:S268
Odunsi K, Wollman RM, Ambrosone CB, Hutson A, McCann SE, Tammela J, Geisler JP, Miller G, Sellers T, Cliby W et al (2005) Detection of epithelial ovarian cancer using H-1-NMR-based metabonomics. Int J Cancer 113(5):782–788
Oliver SG, Winson MK, Kell DB, Baganz F (1998) Systematic functional analysis of the yeast genome. Trends Biotechnol 16(9):373–378
Partington MW, Sinnott B (1964) Case finding in Phenylketonuria. II. The Guthrie test. Can Med Assoc J 91:105–114
Rashed MS (2001) Clinical applications of tandem mass spectrometry: ten years of diagnosis and screening for inherited metabolic diseases. J Chromatogr B Anal Technol Biomed Life Sci 758(1):27–48
Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB (2010) Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 8:13
Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Huh WK, Straughn JM Jr (2009) The timing of normalization of CA-125 levels during primary chemotherapy is predictive of survival in patients with epithelial ovarian cancer. Gynecol Oncol 114(2):242–245
Ross PL, Huang YLN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S et al (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cellular Proteom 3(12):1154–1169
Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, Wiegand R, Berriz GF, Roth FP, Gerszten RE (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112(25):3868–3875
Sahai I, Marsden D (2009) Newborn screening. Crit Rev Clin Lab Sci 46(2):55–82
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 74(12):5463–5467
Schalken JA (2010) Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur Urol 58(1):19–20
Schauer N, Fernie AR (2006) Plant metabolomics: towards biological function and mechanism. Trends Plant Sci 11(10):508–516
Schnackenberg LK, Beger RD (2008) The role of metabolic biomarkers in drug toxicity studies. Toxicol Mech Methods 18(4):301–311
Shah SH, Bain JR, Muehlbauer MJ, Stevens RD, Crosslin DR, Haynes C, Dungan J, Newby LK, Hauser ER, Ginsburg GS, Newgard CB, Kraus WE (2010) Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events. Circ Cardiovasc Genet 3(2):207–214
Smilde AK, Westerhuis JA, Hoefsloot HCJ, Bijlsma S, Rubingh CM, Vis DJ, Jellema RH, Pijl H, Roelfsema F, van der Greef J (2010) Dynamic metabolomic data analysis: a tutorial review. Metabolomics 6(1):3–17
Spears M, Bartlett J (2009) The potential role of estrogen receptors and the SRC family as targets for the treatment of breast cancer. Exp Opin Ther Targets 13(6):665–674
Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231):910–914
Sugimoto M, Wong DT, Hirayama A, Soga T, Tomita M (2010) Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles. Metabolomics 6(1):78–95
The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction (2000) Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 36:959–969
Tiziani S, Lopes V, Günther UL (2009) Early stage diagnosis of oral cancer using 1H NMR-based metabolomics. Neoplasia 11(3):269–276
Tweeddale H, Notley-McRobb L, Ferenci T (1998) Effect of slow growth on metabolism of Escherichia coli, as revealed by global metabolite pool (“Metabolome”) analysis. J Bacteriol 180(19):5109–5116
Urayama S, Zou W, Brooks K, Tolstikov V (2010) Comprehensive mass spectrometry based metabolic profiling of blood plasma reveals potent discriminatory classifiers of pancreatic cancer. Rapid Commun Mass Spectrom 24(5):613–620
van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, Fink D, Ferrero A, McGing P, Harlozinska A, Kainz Ch, Markowska J, Molina R, Sturgeon C, Bowman A, Einarsson R, Goike H (2009) Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaecol Oncol 30(6):609–615
van der Werf MJ, Overkamp KM, Muilwijk B, Coulier L, Hankemeier T (2007) Microbial metabolomics: toward a platform with full metabolome coverage. Anal Biochem 370(1):17–25
van Ravenzwaay B, Cunha GCP, Leibold E, Looser R, Mellert W, Prokoudine A, Walk T, Wiemer J (2007) The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 172(1–2):21–28
Viant MR (2008) Recent developments in environmental metabolomics. Mol Biosyst 4(10):980–986
Vinayavekhin N, Homan EA, Saghatelian A (2010) Exploring disease through metabolomics. ACS Chem Biol 5(1):91–103
Wang Z, Tang WH, Cho L, Brennan DM, Hazen SL (2009) Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition. Arterioscler Thromb Vasc Biol 29(9):1383–1391
Westerhoff HV, Palsson BO (2004) The evolution of molecular biology into systems biology. Nat Biotechnol 22(10):1249–1252
Wilcken B (2007) Recent advances in newborn screening. J Inherit Metab Dis 30(2):129–133
Wilcken B, Wiley V (2008) Newborn screening. Pathology 40(2):104–115
Tang WWH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, Hu B, Troughton RW, Klein AL, Hazen SL (2008) Differential effects of arginine methylation on diastolic dysfunction and disease progression in patients with chronic systolic heart failure. Eur Heart J 29(20):2506–2513
Wishart DS, Knox C, Guo AC, Eisner R, Young N, Gautam B, Hau DD, Psychogios N, Dong E, Bouatra S et al (2009) HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 37:D603–D610
Woo HM, Kim KM, Choi MH, Jung BH, Lee J, Kong G, Nam SJ, Kim S, Bai SW, Chung BC (2009) Mass spectrometry based metabolomic approaches in urinary biomarker study of women’s cancers. Clin Chim Acta 400(1–2):63–69
World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. World Health Organization, Geneva
Wu H, Xue R, Dong L, Liu T, Deng C, Zeng H, Shen X (2009) Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta 648(1):98–104
Zelena E, Dunn WB, Broadhurst D, Francis-McIntyre S, Carroll KM, Begley P, O’Hagan S, Knowles JD, Halsall A, Wilson ID et al (2009) Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. Anal Chem 81(4):1357–1364
Acknowledgments
The authors acknowledge the support of the NIHR Manchester Biomedical Research Centre and The Manchester Academy Health Sciences Centre. WD and RG wish to thank the BBSRC for financial support of The Manchester Centre for Integrative Systems Biology (BB/C008219).
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors Mamas Mamas and Warwick B. Dunn are joint first authors contributing equally to the manuscript.
Rights and permissions
About this article
Cite this article
Mamas, M., Dunn, W.B., Neyses, L. et al. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 85, 5–17 (2011). https://doi.org/10.1007/s00204-010-0609-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-010-0609-6